Table VI.
30-day mortality. Descriptive characteristics of survivors and deceased patients
| Variable | Patients who survived 30 days (N = 26) | Patients who died during 30 days (N = 67) | P-value | |
|---|---|---|---|---|
| Age [years] | Mean ± SD Me (IQR) Min.–max. |
42.04 ±13.56 40.5 (31–51) 24–78 |
50.14 ±12.59 51 (43–58) 25.83 |
0.0069 |
| Hepatic encephalopathy | N (%) | 9 (34.62) | 40 (55.56) | 0.0655 |
| Cirrhosis with ascites | N (%) | 12 (46.15) | 48 (65.75) | 0.0790 |
| Hepatorenal syndrome | N (%) | 3 (11.54) | 21 (28.77) | 0.1352 |
| Alcoholic liver disease | N (%) | 17 (68.00) | 42 (59.15) | 0.4307 |
| GCS score | Mean ± SD Me (IQR) Min.–max. |
12.27 ±4.08 15 (9–15) 3–15 |
9.71 ±4.79 11 (5–14) 3–15 |
0.0041 |
| SOFA score | Mean ± SD Me (IQR) Min.–max. |
9.76 ±4.01 8 (7–12) 5–17 |
15.26 ±3.41 15 (13–17.5) 7–22 |
< 0.0001 |
| APACHE II score | Mean ± SD Me (IQR) Min.–max. |
17.56 ±7.61 17 (13–20) 6–36 |
28.57 ±8.84 28 (22.5–34) 12–55 |
< 0.0001 |
| SAPS II score | Mean ± SD Me (IQR) Min.–max. |
36.00 ±18.83 29 (24–39) 15–81 |
62.08 ±18.86 63 (48–73) 22–103 |
< 0.0001 |
| MELD UNOS Modification score | Mean ± SD Me (IQR) Min.–max. |
27.00 ±5.49 26.5 (23–30) 18–40 |
33.56 ±8.20 34 (27–40) 18–48 |
0.0005 |
| Length of hospital stay [days] | Mean ± SD Me (IQR) Min.–max. |
28.12 ±18.25 27 (13–46) 5–60 |
18.67 ±15.29 15 (7–28) 1–63 |
0.0193 |
| Length of ICU stay [days] | Mean ± SD Me (IQR) Min.–max. |
12.42 ±12.58 7 (5–14) 3–48 |
10.37 ±10.00 8 (3–13) 1–51 |
0.6128 |
| Total bilirubin [mg/dl] | Mean ± SD Me (IQR) Min.–max. |
21.66 ±13.79 20.76 (9.02–32.63) 0.66–45.54 |
17.52 ±11.97 17.51 (6.83–26.64) 0.69–43.22 |
0.1895 |
| Direct bilirubin [mg/dl] | Mean ± SD Me (IQR) Min.–max. |
24.23 ±10.37 22.56 (15.51–32.28) 2.08–43.21 |
20.06 ±8.98 21.16 (13.24–27.4) 0.71–42.85 |
0.1271 |
| Bile acids [µmol/l] | Mean ± SD Me (IQR) Min.–max. |
119.68 ±107.24 95.05 (77.5–127.25) 28.7–549.3 |
101.06 ±75.88 80.4 (51.8–138.7) 28.4–415.8 |
0.3238 |
| Ammonia [µg/dl] | Mean ± SD Me (IQR) Min.–max. |
93.76 ±39.10 92 (67–119) 23–165 |
174.17 ±227.60 108 (73–165) 13–1535 |
0.1334 |
| INR | Mean ± SD Me (IQR) Min.–max. |
1.89 ±0.48 1.915 (1.5–2.31) 1.05–2.7 |
2.64 ±0.97 2.52 (1.8–3.33) 1.24–5.46 |
0.0005 |
| Prothrombin time [s] | Mean ± SD Me (IQR) Min.–max. |
22.10 ±5.39 22.35 (17.2–26.5) 12.1–31.1 |
33.55 ±22.05 30.04 (20.9–42.1) 14.4–189.7 |
0.0005 |
| Creatinine [mg/dl] | Mean ± SD Me (IQR) Min.–max. |
1.59 ±1.45 1 (0.75–1.71) 0.4–6.5 |
2.97 ±2.42 2.43 (1.22–4.12) 0.1–13.52 |
0.0014 |
| Albumin [g/dl] | Mean ± SD Me (IQR) Min.–max. |
3.12 ±0.50 3.11 (2.85–3.49) 2.11–4.15 |
2.60 ±0.67 2.565 (2.105–3.10) 0.9–4.16 |
0.0007 |
| ECLS during ICU stay | N (%) | 17 (65.38) | 29 (39.73) | 0.0238 |
| CRRT during ICU stay | N (%) | 6 (23.08) | 36 (49.32) | 0.0171 |
APACHE – Acute Physiology and Chronic Health Evaluation, CRRT – continuous renal replacement therapy, ECLS – extracorporeal liver support, GCS – Glasgow Coma Scale, ICU – intensive care unit, INR – prothrombin ratio, IQR – interquartile range, MELD UNOS – Model of End-stage Liver Disease United Network for Organ Sharing, SAPS – Simplified Acute Physiology Score, SD – standard deviation, SOFA – Sequential Organ Failure Assessment.